Advancing Engineered TIL (eTIL®) Therapies for the Treatment of Solid Tumors
Time: 11:00 am
day: Conference Day Two
Details:
- Exploring approaches to edit multiple T-cell targets for enhanced therapeutic efficacy against solid tumors
- Immune CRISPRomics® Platform discovered SOCS1 and Regnase-1 as top gene targets enhancing T-cell anti-tumor function
- Developing single and dual-edited eTIL® therapies with inactivation of SOCS1 and Regnase-1
